Epithelial ovarian cancer is the main cause of death from gynaecological cancer in British women, primarily because of its late presentation, which carries a poor prognosis despite available treatment modalities. Interest is focusing on the molecular basis of ovarian cancer in order to uncover new and hopefully effective management strategies.
Strong circumstantial evidence for the location of tumoursuppressor genes (TSGs) can be obtained by observed allele imbalance (loss of heterozygosity, LOH) in tumour DNA compared with a matched constitutional DNA specimen at defined chromosomal loci (Ponder, 1988) . Minimum consensus regions of allele imbalance may lead to isolation and cloning of these 'deleted' genes, and LOH studies in many tumour types have suggested putative TSGs located on chromosome 11. In ovarian cancer, cytogenetic analysis has demonstrated partial deletions of chromosome 11 affecting both the long and short arms (Bello and Rey 1990; Pejovic et al., 1992; Jenkins et al., 1993) . Frequent LOH has been demonstrated at 1 lpl5 (Lee et al., 1989; Ehlen and Dubeau, 1990; Eccles et al., 1992a; Gallion et al., 1992; Vandamme et al., 1992; Viel et al., 1992; Kiechleschwarz et al., 1993) , although not all studies have confirmed this high level of loss (Sato et al., 1991; Zheng et al., 1991; Yangfeng et al., 1992) . A proximal locus at lpl3 (site of WT1) exhibits lower rates of LOH in ovarian cancer (Call et al., 1990; Vandamme et al., 1992; Viel et al., 1992; Bruening et al., 1993) . A minority of these studies have proposed a correlation of I lp LOH with poorly differentiated (Zheng et al., 1991; Kiechleschwarz et al., 1993) and more advanced (Viel et al., 1992) tumours. Molecular studies of the proximal 1 lq region have shown low rates of both LOH and amplification of the 1 1q13 amplicon in ovarian cancer (Lee et al., 1989; Li et al., 1991; Sato et al., 1991; Viel et al., 1992; Foulkes et al., 1993) . In contrast, the only study that has looked specifically at the subtelomeric region of 1llq (Foulkes et al., 1993 ) recorded a high rate of allele imbalance at 1 lq23.3-qter in a small sample of tumours. The advent of highly polymorphic, well-mapped, microsatellites distributed evenly throughout the genome (Weissenbach et al., 1992; Gyapay et al., 1994) and amenable to polymerase chain reaction (PCR) amplification has allowed rapid LOH analysis using small amounts of DNA (Futreal et al., 1992) , which can be derived, if necessary, from archival material.
We have used 10 (CA)" polymorphic microsatellites to determine allele imbalance on chromosome 11 (Cohen et al., 1992 
Results

Molecular analysis
Clinicopathological characteristics of the patient cohort are outlined in Table I . For all ovarian tumours, high levels of LOH were seen in three loci (see Table III Figure 4 Fisher's exact test analysis of co-loss between markers on chromosome 11. none had LOH at DlIS35, and comparing this group with other histologies a trend towards significance was observed for LOH of this marker with non-endometrioid histology (P = 0.04).
Allele imbalance and FIGO stage The only observed trend towards significance was for the association of LOH at Dl S912 with FIGO stage III/IV EOCs (P = 0.035).
Allele imbalance and differentiation grade The only apparent trend towards significance was between Dl S873 LOH and well/moderately differentiated tumours (P = 0.07).
Survival Dl lS912 loss of heterozygosity at 1 lq23.3-24.1 in primary tumours at diagnosis was associated with adverse Kaplan-Meier survival analysis Telomeric 1 lq LOH (Dl 1S925 and DllS912) was significantly associated with adverse survival for patients with ovarian adenocarcinoma (Figure 5 ), and significance was increased when Dl S912 LOH was considered alone (Figure 6 ). Actuarial survival of those without LOH shows 70% survival at 4 years vs. 20% for patients who had lost a Dl S912 allele in their primary is tumour at diagnosis.
Discussion
With a panel of ten highly informative, well-distributed, accurately mapped microsatellite polymorphisms (MSPs), significant levels of chromosome 11 allele imbalance were detected in our population of 60 ovarian tumours. Although the term allele imbalance is used interchangeably with LOH in this paper, we have opted to use this term rather than LOH since imbalance can also be a consequence of allelespecific amplification and need not necessarily imply deletion of a region of DNA. Furthermore, amplification of a region of DNA is not mutually exclusive with loss of function at a tumour-suppressor locus; loss of a chromosome or subchromosomal region may occur with reduplication of the other allele/chromosome, and amplification of a region of DNA is not necessarily associated with gain of function if accompanying inactivating mutations are involved. In contrast to findings with chromosome 17 (Steel et al., 1994) , in which whole homologue or whole arm loss is common, interstitial and small terminal deletions are in fact more common in chromosome 11 in this same group of ovarian tumours. A highly significant association between allele imbalance on 17p and 17q in this material has been observed previously (Fisher's exact test, P = 0.0007; data not presented). No such association is observed for imbalance on I lp and 1 lq (P = 0.65) as a whole, and this argues for caution in the interpretation of allelotyping data that utilise only one or two loci per chromosome arm where no previous biological hypothesis associates that chromosome arm with involvement in neoplasia.
However, relationships for allele imbalance between distant chromosome 11 loci do occur; not only between adjacent sites (which are likely to reflect larger deletions). Significant associations do occur between two distant loci while intervening loci are excluded from the relationship, as shown for example by D1IS912/Dl1S935 and D1IS935/Dl1S922 (at borderline significance). These pairs of loci may harbour genes which are cooperatively inactivated as part of a multistep process. Consensus analysis of those EOCs with partial deletion suggests at least three distinct regions of allele imbalance, at llplS. 5-pl5.3, llq23.3-24.1 and llpl2-ql4.3 .
In contrast to previous reports (Zheng et al., 1991; Kiechleschwarz et al., 1993) , we found no significant association between differentiation grade and allele imbalance at the llpl5 region (despite 67% LOH) in our sample of EOCs, and this may reflect the lack of uniformity in ovarian cancer grading methodology; nor could we confirm an association between llpl5 LOH and advanced stage disease (Viel et al., 1992) , although there appeared to be a non-significant trend for both these parameters (Figure 2 ). Dl lS922 LOH
(1 lpl 5.5) did correlate at a borderline level of significance (P=0.046) with LOH at Dl S935. (Significant LOH rates have been detected in several studies at 11 p1 3, near the site of WTI, although direct analysis of the WT1 locus suggests that it is not the gene involved; Bruening et al., 1993; Viel et al., 1994.) There was also evidence of significant LOH at Dl S922 in benign and borderline tumours. With this high level of loss in EOCs, and without significant correlations with advanced disease/poor prognosis subgroups, the likelihood is that an 18.6 Mb interval within I lplS houses a gene involved at an early stage in ovarian carcinogenesis, occurring as part of the development of benign and borderline tumours and also detectable at roughly similar rates in adenocarcinoma. Allele loss at Dl1IS569 (1 lplS.3) is low (12.5%) in benign and borderline tumours, but is much higher in carcinomas, and there is no difference in LOH rate This raises the possibility of a second locus at lIp1 5.3 which is inactivated as part of the development of frank adenocarcinoma (albeit at an early stage of adenocarcinoma development).
We have confirmed and extended (in both numbers and chromosomal position) the recent finding of extensive allele loss distal to 1Iq23.3 (Foulkes et al., 1993) , with 67% of EOCs exhibiting LOH at llq23.3-24.1 in our sample. Our proximal marker (Dl1S925) in this region maps about 1.2 Mb telomeric to the most distal marker in the study of Foulkes et al. Loss of heterozygosity at the distal MSP (Dl S912) at 1 1q24.1 is significantly associated with adverse survival and advanced stage, although the latter P-value, at 0.035, is borderline.
No borderline tumours exhibited allele imbalance at Dl lS912. Allele imbalance at the subtelomeric region at Dl 1S912 showed significant correlation with Dl lS897 (l1q23.1) and DllS935 (llpl3 in the region of WTI). These findings suggest that a TSG acting primarily as a 'progression suppressor' may be located at llq23.3-24.1 (or telomeric), and that its inactivation may be a significant late event in the pathogenesis of epithelial ovarian cancer. The llpl2-ql4.3 region (which is a large region containing the centromeric half of llq), although exhibiting high levels of loss, does not appear to segregate significantly with any particular parameter, although there is a non-significant trend towares LOH in association with better prognosis tumours. Allele imbalance in this region does, however, segregate significantly with imbalance of the 1 lq subtelomeric region. Dl S873 LOH at 1 lql4-q22 seems to correlate with favourable clinicopathological parameters: higher LOH rates are observed in those with mucinous histology, early FIGO stage and well/moderately differentiated tumours. Higher rates of allele loss at DlIS873 are seen in those patients remaining alive (also seen at the neighbouring locus, Dl S905 at 1 1p13-12). These findings suggest the possibility that some well-differentiated, early FIGO stage carcinomas may belong to a genetically distinct subcategory of EOC rather than being simply precursors of aggressive late-stage disease (Figure 7) , and that allele loss in the 1 Ip12-q22 region may confer changes incompatible with rapid progression of the disease, e.g. deletion of an oncogene locus essential for tumour progression. It is possible that LOH detected in this region could reflect amplification of the 1 1q13 region similar to that observed in breast cancer (Karlseder et al., 1994) , and we have not ruled out this possibility in the present study, although previous studies of this region in ovarian cancer (Foulkes et al., 1993) Chromosome 11 allele imbalance in ovarian tumours H Gabra et al 374 amplification occurs infrequently. However, the explanation for our findings of better prognosis associated with allele loss at this locus remains obscure and requires further work.
The absence of LOH at Dl S873 and Dl S35 specifically in endometrioid adenocarcinoma is of considerable interest, though the finding approached statistical significance only for the latter MSP (P = 0.04). Dl 1S35 lies about 160 kb from the site of the progesterone receptor (PgR) gene. At least six studies have reported that endometrioid tumours contain PgR levels that are elevated relative to other histological types (Slotman and Rao, 1988) . Furthermore, there is evidence that, in breast cancer, gene dosage, although secondary to regulatory change, plays a significant role in determining hormone receptor levels: tumours that are cytogenetically 6q -/1 lq -have half as many oestrogen receptors (ER) and PgRs as tumours without losses on 6q or 1 lq (Magdelenat et al., 1994) . We would therefore speculate that there may be a role for the PgR gene in the regulation of histological subtypes of ovarian cancer, and possibly that its structural disruption contributes to the generation of adverse histological and prognostic subtypes at a relatively early stage in the development of ovarian cancer.
The findings in this study extend the previous observations of distinctive patterns of aneusomy or molecular aberrations in ovarian cancers belonging to different clinicopathological subgroups. They do not imply that LOH at each of the defined regions of chromosome 11 represents independent prognostic factors, although 1 lq subtelomere imbalance should perhaps be subjected to a large prospective study.
Of more immediate relevance is the application of the observed correlations synthesis of a multistep model of ovarian carcinogenesis (Figure 7 ). In this model, there is not only multistep, but also multipath, progression of ovarian cancer, postulating, for example, the involvement of q14.3-q22 imbalance ;in a biologically distinct subpopulation of early EOC.
Extensive chromosome 17 microsatellite and restriction fragment length polymorphism (RFLP) analysis of this same cohort of patients has been performed in our laboratory (Eccles et al., 1992b; Steel et al., 1994) , and we are currently extending our analysis to correlations between regions of LOH on chromosomes 11 and 17 and their relationship to clinicopathological parameters. In addition, more detailed mapping of LOH within the llq23.3-qter region to better define the imbalance peak is in progress. This will also determine if there are regions telomeric to llq24 with low rates of LOH and address the possibility that these observed losses are simply due to non-specific telomeric high-frequency breakages as a consequence of neoplasia rather than putative tumour-suppressor genes at these sites.
